Abstract 329: ST266 Attenuates Neointima Formation After Arterial Balloon Angioplasty in Rats

Objective: Post-angioplasty restenosis due to neointima formation has been attributed to the inflammatory response after acute endoluminal injury. ST266 (Noveome Biotherapeutics, Inc.) a novel secretome derived from proprietary GMP-cultured human Amnion-Derived Multipotent Progenitor (AMP) cells, has been shown to be anti-inflammatory and to promote wound healing. This study examined the therapeutic potential of ST266 in a rat arterial balloon angioplasty model. Methods: Animals were randomly divided in the following groups (N=7): no-treatment (noTx), systemic ST266, systemic AMPs and local AMP implants. Neointima hyperplasia was induced in the iliac artery of Sprague-Dawley male rats using a 2F Fogarty embolectomy catheter. After surgery, animals in ST266 groups received 0.1, 0.5 or 1ml IV ST266 q.d. In the systemic AMP groups, single-dose (SD) of 0.5 million (M) or 1 M AMPs was injected via Inferior Vena Cava after the angioplasty. In AMP implant experiment 1 M, 5 M or 20 M AMPs were implanted in 300 μL...